Press Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 25, 2017Study evaluated safety, dose limiting toxicities, related maximum tolerated dose and indication of anti-tumor activity in patients with advanced or metastatic solid tumors
-
Apr 13, 2017Revised model factoring in PCM-075 (AML drug) as the key driver of the company going forward - sets $4 target price.
-
Apr 12, 2017Maxim Group upgrades Trovagene from a "hold" position to a "buy" position based on PCM-075 (AML drug candidate) as the key driver of the company going forward
-
Mar 15, 2017Announces restructuring program to support its expansion into precision cancer therapeutics
-
Mar 7, 2017Authors conclude that ctDNA testing demonstrates clinical utility in assessing disease burden and response to therapy
-
Jan 24, 2017Performance of Trovera™ ctDNA KRAS in blood and urine has similar concordance to standard of care tissue molecular diagnostics
-
Jan 12, 2017Seven new partners to commercialize Trovera™ liquid biopsy tests in Europe and the Middle East
-
Nov 30, 2016Companies to develop and commercialize multiplexed urine and blood ctDNA liquid biopsy assay kits for global distribution
-
Oct 4, 2016Trovera™ liquid biopsy test selected by the Pancreatic Cancer Action Network for its industry-leading sensitivity and ability to rapidly and quantitatively assess response to therapy
-
Aug 17, 2016BCBS Illinois expands patient access to Trovera™ tests for 8.1 million covered lives
-
Aug 9, 2016Author concludes that confirmation of EGFR mutational status using urine ctDNA analysis should be considered in treatment decision-making
-
Jul 26, 2016Data confirms EGFR Activating Mutations and EGFR T790M in metastatic non-small cell lung cancer (NSCLC) diagnosis in urine and blood with high sensitivity and specificity
-
Jul 6, 2016Trovagene's KRAS ctDNA liquid biopsy test will be at the forefront of research partnership with Dr. Diane Simeone at University of Michigan Health System
-
Jun 6, 2016Results validate urine ctDNA testing as an alternative to tissue and plasma based on a large prospective study of T790M detection and patient response to an EGFR tyrosine kinase inhibitor
-
May 19, 2016Results from 213 patient study demonstrates use of urinary ctDNA as a stand-alone test for the highly sensitive detection of EGFR T790M mutations for therapy selection
-
May 13, 201692.9% of metastatic pancreatic cancer patients determined to be KRAS positive using Trovagene's Precision Cancer Monitoring assay
-
Apr 15, 2016Confirmation of BRAF V600E mutational status and quantitative monitoring of changes in urinary ctDNA used to assess response to novel combination drug therapy for colorectal neuroendocrine tumors